Similar articles

• The impact of suppressing the renin-angiotensin system on atrial fibrillation.

  Kalus JS, Coleman CI, White CM. Kalus JS, et al. J Clin Pharmacol. 2006 Jan;46(1):21-8. doi: 10.1177/0091270005283284. J Clin Pharmacol. 2006. PMID: 16397280
• Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.

  Makkar KM, Sanoski CA, Spinler SA. Makkar KM, et al. Pharmacotherapy. 2009 Jan;29(1):31-48. doi: 10.1592/phco.29.1.31. Pharmacotherapy. 2009. PMID: 19113795 Review.
• [Innovative therapeutic approach to atrial fibrillation: AT1-receptor blocker].

  Goette A. Goette A. Dtsch Med Wochenschr. 2006 Aug 25;131(34-35 Suppl 4):S103-7. doi: 10.1055/s-2006-949185. Dtsch Med Wochenschr. 2006. PMID: 16921445 Review. German. No abstract available.
• Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.

  Anand K, Mooss AN, Hee TT, Mohiuddin SM. Anand K, et al. Am Heart J. 2006 Aug;152(2):217-22. doi: 10.1016/j.ahj.2006.01.007. Am Heart J. 2006. PMID: 16875900
• Renin-angiotensin system inhibitors and atrial fibrillation.

  Arbel Y, Glikson M. Arbel Y, et al. Isr Med Assoc J. 2005 Jun;7(6):388-91. Isr Med Assoc J. 2005. PMID: 15984384 Review. No abstract available.